an older ADC that uses a tubulin inhibitor (antimitotic agent) DM1 as its payload. Third, Enhertu’s cysteine-based conjugation process is able to achieve a high drug-to-antibody ratio of around ...

Serum from immunized mice diluted 1: 50, rabbit α/β-tubulin antibody (Cell Signaling Technology) diluted 1: 1000 and anti-Ig kappa light chain antibody (Southern Biotech) diluted 1: 5000 in TBS-T ...

1Tumor Immune Analysis Core, Office of Research & Development, Taipei Medical University, Taipei, Taiwan.

The AVC-Booster design surpasses the best qualities of first-generation antibodies, checkpoint inhibitors, T-cell engagers, and antibody-drug conjugates (ADCs). “AVC-Boosters have the potential to ...

Our team of proven drug developers is advancing an antibody-drug conjugate with our proprietary linker technology, a T-cell engager with wide therapeutic window, and a multi-functional checkpoint ...

An anti-IL1RAP ADC was generated from an antibody selected from Cantargia's unique library of IL1RAP-targeting antibodies and conjugated to a tubulin-targeting payload using ImmunoGen (now part of ...

The FDA has approved Akeso’s penpulimab-kcqx, a PD-1 monoclonal antibody, for two indications treating nasopharyngeal carcinoma (NPC). The drug is now indicated in combination with chemotherapy as a ...

SAN FRANCISCO--(BUSINESS WIRE)--Synthetic Design Lab, a next-generation antibody-drug conjugate (ADC) company advancing its novel SYNTHBODY therapeutic platform against a range of cancer ...

Full results from the trial evaluating Akeso’s first-in-class PD-1/VEGF bispecific antibody are expected to be presented later this year at a medical conference. 1 "The interim analysis results from ...

Like the name says, antisperm antibodies fight sperm. It happens when the immune system mistakenly targets sperm in a man’s semen as an invader and damages or kills it. Antisperm antibodies aren ...